Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: a systematic review and network meta-analysis
Background and Objective Janus kinase (JAK) inhibitors (JAKinibs) are effective for inflammatory bowel disease (IBD), but their cardiovascular safety is inconclusive. We aim to assess the cardiovascular risks associated with JAKinibs in IBD patients.Patients and Methods Systematic searches of seven...
Saved in:
Main Authors: | Huibin Yang, Ting An, Yuxuan Zhao, Xiaojing Shi, Bangmao Wang, Qingyu Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2025-12-01
|
Series: | Annals of Medicine |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/07853890.2025.2455536 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Janus kinase inhibitor treatment for inflammatory diseases: excess or no excess risk of venous thromboembolism?
by: Yachar Dawudi, et al.
Published: (2025-01-01) -
Janus kinase inhibitors and biologics for treatment of livedoid vasculopathy: a systematic review
by: Yu Liu, et al.
Published: (2025-12-01) -
Increased risk of Pneumocystis jirovecii colonization in rheumatoid arthritis patients on biologics and Janus kinase inhibitor
by: Ya-Chun Huang, et al.
Published: (2025-02-01) -
Weight gain secondary to the use of oral Janus kinase inhibitors: A systematic review and meta-analysis
by: Grace Xiong, BHSc, et al.
Published: (2025-04-01) -
Screening for Janus kinase-2 exon 12 mutations among Janus kinase-2 V617F-negative polycythemia vera suspected Iraqi patients
by: Mushtaq M. Khazeem, et al.
Published: (2024-12-01)